217 related articles for article (PubMed ID: 33568749)
41. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P
Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648
[TBL] [Abstract][Full Text] [Related]
42. Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
Nikhil K; Haymour HS; Kamra M; Shah K
Br J Cancer; 2021 Mar; 124(5):995-1008. PubMed ID: 33311589
[TBL] [Abstract][Full Text] [Related]
43. GR silencing impedes the progression of castration-resistant prostate cancer through the JAG1/NOTCH2 pathway via up-regulation of microRNA-143-3p.
Zhang L; Jiang H; Zhang Y; Wang C; Xia X; Sun Y
Cancer Biomark; 2020; 28(4):483-497. PubMed ID: 32568179
[TBL] [Abstract][Full Text] [Related]
44. Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway.
Qin C; Sheng Z; Huang X; Tang J; Liu Y; Xu T; Qiu X
Prostate; 2020 Sep; 80(13):1134-1144. PubMed ID: 32628304
[TBL] [Abstract][Full Text] [Related]
45. Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer.
Wang Z; Wu D; Ng CF; Teoh JY; Yu S; Wang Y; Chan FL
Endocr Relat Cancer; 2018 Jan; 25(1):35-50. PubMed ID: 29042395
[TBL] [Abstract][Full Text] [Related]
46. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
[TBL] [Abstract][Full Text] [Related]
47. LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
Han C; Yu G; Mao Y; Song S; Li L; Zhou L; Wang Z; Liu Y; Li M; Xu B
PLoS One; 2020; 15(11):e0240801. PubMed ID: 33137125
[TBL] [Abstract][Full Text] [Related]
48. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
49. A new tumorgraft panel to accelerate precision medicine in prostate cancer.
Béraud C; Bidan N; Lassalle M; Lang H; Lindner V; Krucker C; Masliah-Planchon J; Potiron E; Lluel P; Massfelder T; Allory Y; Misseri Y
Front Oncol; 2023; 13():1130048. PubMed ID: 37305585
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
51. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
52. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
[TBL] [Abstract][Full Text] [Related]
54. PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2.
Zhao R; Feng T; Gao L; Sun F; Zhou Q; Wang X; Liu J; Zhang W; Wang M; Xiong X; Jia W; Chen W; Wang L; Han B
J Exp Clin Cancer Res; 2022 Apr; 41(1):125. PubMed ID: 35382861
[TBL] [Abstract][Full Text] [Related]
55. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
56. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
57. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
[TBL] [Abstract][Full Text] [Related]
58. Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling.
Van Hemelryk A; Tomljanovic I; de Ridder CMA; Stuurman DC; Teubel WJ; Erkens-Schulze S; Verhoef EI; Remmers S; Mahes AJ; van Leenders GJLH; van Royen ME; van de Werken HJG; Grudniewska M; Jenster GW; van Weerden WM
Cells; 2022 Nov; 11(22):. PubMed ID: 36429059
[TBL] [Abstract][Full Text] [Related]
59. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.
Parolia A; Venalainen E; Xue H; Mather R; Lin D; Wu R; Pucci P; Rogalski J; Evans JR; Feng F; Collins CC; Wang Y; Crea F
Mol Oncol; 2019 May; 13(5):1121-1136. PubMed ID: 30776192
[TBL] [Abstract][Full Text] [Related]
60. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
